884494-85-3 Usage
General Description
5-Chloro-6-methoxynicotinic acid is a chemical compound with the molecular formula C7H6ClNO3. It is a derivative of nicotinic acid, also known as vitamin B3, and is commonly used in the synthesis of pharmaceuticals and agrochemicals. 5-Choro-6-methoxynicotinic acid is a white to off-white powdered solid, and it is insoluble in water but soluble in organic solvents. It is a versatile building block in organic synthesis, and its unique structure makes it a valuable intermediate in the production of various drugs and agricultural products. Additionally, 5-Chloro-6-methoxynicotinic acid exhibits potential biological activity and may have therapeutic applications in the treatment of certain diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 884494-85-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,4,4,9 and 4 respectively; the second part has 2 digits, 8 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 884494-85:
(8*8)+(7*8)+(6*4)+(5*4)+(4*9)+(3*4)+(2*8)+(1*5)=233
233 % 10 = 3
So 884494-85-3 is a valid CAS Registry Number.
InChI:InChI=1/C7H6ClNO3/c1-12-6-5(8)2-4(3-9-6)7(10)11/h2-3H,1H3,(H,10,11)
884494-85-3Relevant articles and documents
PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS
-
Page/Page column 24, (2011/09/20)
The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituents are as defined in the claims.
PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS
-
Page/Page column 65, (2009/04/25)
The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituants are as defined in the claims.
